<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101601398</journal-id>
<journal-id journal-id-type="pubmed-jr-id">42374</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Opin Orphan Drugs</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Opin Orphan Drugs</journal-id>
<journal-title-group>
<journal-title>Expert opinion on orphan drugs</journal-title>
</journal-title-group>
<issn pub-type="epub">2167-8707</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27833825</article-id>
<article-id pub-id-type="pmc">5098502</article-id>
<article-id pub-id-type="doi">10.1517/21678707.2016.1148597</article-id>
<article-id pub-id-type="manuscript">NIHMS797926</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Taveira-DaSilva</surname>
<given-names>Angelo M.</given-names>
</name>
<degrees>M.D., Ph.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moss</surname>
<given-names>Joel</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room 6D03, MSC 1590, Bethesda, Maryland 20892-1590, USA
</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Corresponding author: <email>dasilvaa@nhlbi.nih.gov</email>, Tel: 301-451-4950, Fax: 301-496-2363</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>25</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>7</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>07</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>4</volume>
<issue>4</issue>
<fpage>369</fpage>
<lpage>378</lpage>
<!--elocation-id from pubmed: 10.1517/21678707.2016.1148597-->
<self-uri xlink:href="http://www.tandfonline.com/doi/full/10.1517/21678707.2016.1148597"></self-uri>
<abstract>
<sec id="S1">
<title>Introduction</title>
<p id="P1">Lymphangioleiomyomatosis (LAM) is a disease of women characterized by cystic lung destruction, lymphatic involvement, and renal angiomyolipomas.</p>
</sec>
<sec id="S2">
<title>Areas covered</title>
<p id="P2">LAM is caused by proliferation of abnormal smooth muscle-like LAM cells containing mutations and perhaps epigenetic modifications of the <italic>TSC1</italic> or <italic>TSC2</italic> genes, which encode, respectively, hamartin and tuberin, two proteins controlling the mechanistic target of rapamycin (mTOR) signaling pathway. LAM occurs sporadically or in association with tuberous sclerosis complex. LAM may present with dyspnea, recurrent pneumothorax or chylothorax. Pulmonary function tests show reduced flow rates and lung diffusion capacity. Exercise testing may reveal hypoxemia and ventilatory limitation. The severity and progression of disease may be assessed by computer tomography, and pulmonary function and exercise testing. mTOR inhibitors, (e.g., sirolimus) are effective in stabilizing lung function, and reducing the size of chylous effusions, lymphangioleiomyomas, and angiomyolipomas.</p>
</sec>
<sec id="S3">
<title>Expert opinion</title>
<p id="P3">Different clinical phenotypes including variable rates of disease progression and variable responses to therapy are seen in LAM patients. No one test is available that predicts the course of disease at the time of diagnosis. Further research regarding the molecular biology of LAM clinical phenotypes is warranted. Recent advances in the characterization of the pathogenesis of LAM are leading to the development of new therapies.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Lymphangioleiomyomatosis</kwd>
<kwd>Tuberous sclerosis complex (TSC)</kwd>
<kwd><italic>TSC 1</italic> and <italic>TSC2</italic> mutations</kwd>
<kwd>mTOR</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>